Who are Johnson & Johnson's decision-makers?

Joaquin Duato, Chairman and CEO since January 2022 (Chairman since January 2023), is a biochemist who has spent his entire 35+ year career at J&J, most recently running the pharmaceutical segment before ascending to the top role. His tenure has been defined by the Kenvue spin-off (2023), a $30B+ cardiovascular M&A spree (Abiomed and Shockwave), and steering the company toward its first $100B revenue year in 2026. In May 2026, Duato published an op-ed in Fortune championing U.S. biopharmaceutical innovation policy, underscoring J&J's $55B U.S. investment commitment.

The Innovative Medicine business is co-led by Jennifer Taubert (EVP, Worldwide Chairman) and John Reed (EVP, R&D) — overseeing J&J's $60.4B drug business and $14.7B annual research budget. Tim Schmid (EVP, Worldwide Chairman of MedTech) leads the $33.8B device segment across 75,000+ employees. Joe Wolk (CFO) manages capital allocation and M&A diligence, while Jim Swanson (CIO) drives the enterprise technology, AI, and GenAI agenda across 4,000+ IT professionals in 50 countries.

Buying authority at J&J is distributed across three tiers. For strategic enterprise technology and large vendor decisions (ERP, cloud platforms, AI programs), Jim Swanson's (CIO) organization is the primary champion, co-owning decisions with the relevant business segment head — Jennifer Taubert for Innovative Medicine commercial tools or Tim Schmid for MedTech manufacturing and operations tools. Finance sign-off above defined thresholds flows through Joe Wolk's organization, with global procurement teams in J&J's shared services layer handling vendor contracting and GPO negotiations.

For pharmaceutical commercial tools (CRM, medical affairs platforms, market access analytics, field force enablement), Innovative Medicine commercial and marketing leadership within Taubert's organization owns the budget. For MedTech manufacturing technology, supply chain, and IoT platforms, Kathryn Wengel (EVP, Chief Technical Operations and Risk Officer) is the key decision-maker alongside Schmid. A separate corporate IT leadership layer — including Swanson's deputy Chris Della Rocca (SVP, Corporate Business Technology) — handles enterprise-wide infrastructure, cybersecurity, and shared technology platforms across both segments.

Post-Kenvue, J&J runs a two-segment model: Innovative Medicine and MedTech, each with its own worldwide chairman reporting directly to Duato. This is simpler than the historic three-segment structure (pharma, medical devices, consumer) and has allowed faster capital reallocation into high-growth platforms. Each segment operates semi-autonomously with its own commercial, R&D, and operational leadership, but shares enterprise infrastructure (IT, finance, HR, legal) through J&J's global shared services function.

The pending DePuy Synthes separation (announced October 2025; Namal Nawana as designated president) will further tighten MedTech's focus onto cardiovascular, surgery, and vision. Once completed, J&J's MedTech segment will have a sharper growth profile and higher average margins, making it more comparable to pure-play cardiovascular device companies like Shockwave's former standalone profile. The enterprise shared services function — handling finance, HR, IT infrastructure, and procurement across 60+ countries — means enterprise vendors who land a J&J deal gain scale efficiencies, as the same contract rolls across geographies under a single master services agreement.